.Attribute Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view calls for inclusion of people with MASLD as well as dimension of liver outcomes in cardio-- kidney-- metabolic trials, when information propose mechanistically probable perks and also clinical security-- and also lays out factors to consider for test design and regulatory commendation.